Rachel Houghton, managing director at Business Moves Group (BMG), explores how pharmaceutical manufacturers can navigate complex regulatory landscapes and safeguard sensitive equipment to ensure seamless international workplace transitions.
BMG
In pharmaceutical manufacturing, precision and compliance are non-negotiable, especially when managing international workplace transitions. Navigating complex regulatory landscapes and safeguarding sensitive equipment requires sensitive planning and trusted partnerships. Rachel Houghton, managing director at BMG, details practical strategies to minimise disruption and maintain operational continuity.
Medicine in motion: International moves in pharmaceutical manufacturing
In pharmaceutical manufacturing, precision is a necessity. Delivering critical pharmaceuticals to patients is essential, and every process, from research to production, is governed by stringent regulations and exacting standards.
And pharmaceutical organisations are expanding. In the UK alone, the life sciences sector is valued at £100 billion, and the government has announced a new Life Sciences Sector plan to strengthen its industrial strategies.
When biopharma manufacturers expand into new sites, whether in the same country or a new territory, these stakes are even higher. Sensitive equipment, critical timelines, and diverse compliance frameworks converge, making the margin for error vanishingly small.
Successful international moves require meticulous planning with trusted partners to navigate changing regulatory landscapes and protect sensitive equipment. With the right global partners, these moves can be managed effectively, to ensure continuity, compliance, and ultimately, care for the science that needs to be maintained.
The cost of fragmentation
Relying on a patchwork of local suppliers may seem convenient in the short term, but it can have profoundly negative effects on global workspace moves. Fragmented delivery and inconsistent standards can increase risk; If one part of a supply chain fails, this can result in operational downtime, employee stress, and damage to product output and brand reputation. In fact, 64% of employees report moves as stressful, which can directly impact productivity and morale.
To mitigate these risks, organisations partner with centralised delivery models that are supported by international networks. This strategy unites consistent standards with the flexibility of local experts, so that every move remains at a consistent high standard.
Strategic planning for high-stakes moves
Detailed planning is the foundation of any successful move. In pharmaceutical environments, this means accounting for specialist equipment that requires trained personnel, such as those certified in heavy lifting or stair lift operation.
It also involves coordinating with site managers to avoid clashes with ongoing or upcoming projects. Identifying a time slot that minimises downtime and disruption requires collaboration across multiple stakeholders.
A comprehensive asset audit is essential. Understanding what needs to move, what can be stored, and what should be decommissioned allows for informed decision-making. High-value items should be clearly tagged, and their condition documented. This supports insurance and compliance requirements and ensures that movers handle them with the necessary care.
Leveraging trusted networks
Using an international network provides a standardised approach across borders. By blending central coordination with local delivery, pre- and post-move calibration sessions can prevent common pitfalls and ensure that equipment is functioning correctly at new sites. Rather than having to spend time onboarding new suppliers in each country, a ready-made network keeps the moving process as swift as possible.
International networks like the Office Moving Alliance remain in constant communication, aligning key performance indicators between diverse teams and preventing any regulatory surprises, including standards like Europe’s Good Distribution Practice guidelines.
Clearly communicating change
Any relocation can prompt uncertainty among employees, especially if it is across countries. Clear, proactive communications should address the rationale for the move, the benefits for the team, and the timeline of key milestones. For example, will the new facility support more advanced projects or offer better professional development opportunities?
Employers need a communication plan that signposts employees to the key dates they need to know, relevant managers or senior leaders they can bring their concerns to, and general FAQs for any pressing questions.
Managing critical equipment with care
Centrifuges, incubators and microscopes. These pieces of equipment are not only costly investments, they are critical to operations. Damage or loss can result in significant costs and delays. Movers need to be trained in technical distribution and understand the specific handling requirements of each item. They should also be knowledgeable about the materials or special cases needed for packaging and maintain clear communication with specialist operators at pharmaceutical sites.
During the packaging stage, protective covers and strategic van loading are essential. Items like medical fridges may need to remain powered throughout the move to maintain temperature, and trained professionals should oversee equipment reassembly.
Teams should also undergo regular training to stay updated on the latest safety practices and technologies, as well as carry out comprehensive insurance coverage, giving manufacturers peace of mind.
Embedding sustainability
Workplace transitions are at risk of being wasteful without a clear strategy. Aligning stakeholder sustainability goals can maintain circular economic principles and meet corporate ESG goals. Rather than package up and move items across countries without considering their environmental impact, an asset audit should identify items for resale, refurbishment, donation, or recycling.
Every piece of furniture, laboratory equipment and operational asset carries a carbon footprint, and finding the lowest carbon pathway prevents this footprint from increasing unnecessarily.
If pharmaceutical equipment is best off not being moved, it could be resold to offset relocation costs, or donated to local businesses, schools, or charities to boost local community engagement.
Where reuse is not possible, recycling is the best option to prevent significant landfill contribution. This approach supports circular economic principles, aligning international moves with organisations’ environmental commitments wherever possible.
Conclusion: Planning with precision
As pharmaceutical organisations seek to expand globally, the need for consistency and high-quality partners is growing. A fragmented approach towards these transitions only increases risk, but a centralised and network-driven model can offer consistency and prioritise compliance.
Meticulous auditing, move planning, and consistent team communication can ensure that international moves support, rather than hinder, their operational expansions.
In a sector where precision is paramount, and end products can be lifesaving, the way you move matters.